Jeffrey L Gunter

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. pmc Methodological considerations for measuring rates of brain atrophy
    Jeffrey L Gunter
    Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    J Magn Reson Imaging 18:16-24. 2003
  2. pmc Measurement of MRI scanner performance with the ADNI phantom
    Jeffrey L Gunter
    Mayo Clinic and Foundation, Rochester, Minnesota 55902, USA
    Med Phys 36:2193-205. 2009
  3. pmc Shapes of the trajectories of 5 major biomarkers of Alzheimer disease
    Clifford R Jack
    Department of Radiology, Mayo Clinic and Foundation, Rochester, Minnesota, USA
    Arch Neurol 69:856-67. 2012
  4. pmc Selective worsening of brain injury biomarker abnormalities in cognitively normal elderly persons with β-amyloidosis
    David S Knopman
    Mayo Clinic Alzheimer s Disease Research Center, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    JAMA Neurol 70:1030-8. 2013
  5. pmc An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease
    Clifford R Jack
    Department of Radiology, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Ann Neurol 71:765-75. 2012
  6. doi request reprint Elevated occipital β-amyloid deposition is associated with widespread cognitive impairment in logopenic progressive aphasia
    Jennifer L Whitwell
    Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA
    J Neurol Neurosurg Psychiatry 84:1357-64. 2013
  7. pmc Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity
    Clifford R Jack
    From the Departments of Radiology C R J, V L, P V, D T J, M L S, J L G, B E G, Health Sciences Research H J W, S D W, M M M, V S P, and Neurology D S K, R C P, Mayo Clinic and Foundation, Rochester, MN
    Neurology 81:1732-40. 2013
  8. pmc Effect of lifestyle activities on Alzheimer disease biomarkers and cognition
    Prashanthi Vemuri
    Department of Radiology, Mayo Clinic and Foundation, 200 First St SW, Rochester, MN 55905, USA
    Ann Neurol 72:730-8. 2012
  9. pmc Antemortem differential diagnosis of dementia pathology using structural MRI: Differential-STAND
    Prashanthi Vemuri
    Department of Radiology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Neuroimage 55:522-31. 2011
  10. pmc Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease
    Clifford R Jack
    Department of Radiology, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Brain 133:3336-48. 2010

Detail Information

Publications24

  1. pmc Methodological considerations for measuring rates of brain atrophy
    Jeffrey L Gunter
    Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    J Magn Reson Imaging 18:16-24. 2003
    ..To systematically compare two techniques for measuring brain atrophy rates from serial magnetic resonance imaging (MRI) studies...
  2. pmc Measurement of MRI scanner performance with the ADNI phantom
    Jeffrey L Gunter
    Mayo Clinic and Foundation, Rochester, Minnesota 55902, USA
    Med Phys 36:2193-205. 2009
    ..If undetected, these errors would have contributed to imprecision in quantitative metrics at over 25% of all enrolling ADNI sites...
  3. pmc Shapes of the trajectories of 5 major biomarkers of Alzheimer disease
    Clifford R Jack
    Department of Radiology, Mayo Clinic and Foundation, Rochester, Minnesota, USA
    Arch Neurol 69:856-67. 2012
    ..To characterize the shape of the trajectories of Alzheimer disease biomarkers as a function of Mini-Mental State Examination (MMSE) score...
  4. pmc Selective worsening of brain injury biomarker abnormalities in cognitively normal elderly persons with β-amyloidosis
    David S Knopman
    Mayo Clinic Alzheimer s Disease Research Center, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    JAMA Neurol 70:1030-8. 2013
    ....
  5. pmc An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease
    Clifford R Jack
    Department of Radiology, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Ann Neurol 71:765-75. 2012
    ..A workgroup commissioned by the Alzheimer's Association (AA) and the National Institute on Aging (NIA) recently published research criteria for preclinical Alzheimer disease (AD). We performed a preliminary assessment of these guidelines...
  6. doi request reprint Elevated occipital β-amyloid deposition is associated with widespread cognitive impairment in logopenic progressive aphasia
    Jennifer L Whitwell
    Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA
    J Neurol Neurosurg Psychiatry 84:1357-64. 2013
    ....
  7. pmc Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity
    Clifford R Jack
    From the Departments of Radiology C R J, V L, P V, D T J, M L S, J L G, B E G, Health Sciences Research H J W, S D W, M M M, V S P, and Neurology D S K, R C P, Mayo Clinic and Foundation, Rochester, MN
    Neurology 81:1732-40. 2013
    ..To estimate the incidence of and to characterize cognitive and imaging findings associated with incident amyloid PET positivity...
  8. pmc Effect of lifestyle activities on Alzheimer disease biomarkers and cognition
    Prashanthi Vemuri
    Department of Radiology, Mayo Clinic and Foundation, 200 First St SW, Rochester, MN 55905, USA
    Ann Neurol 72:730-8. 2012
    ....
  9. pmc Antemortem differential diagnosis of dementia pathology using structural MRI: Differential-STAND
    Prashanthi Vemuri
    Department of Radiology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Neuroimage 55:522-31. 2011
    ..8%). The proposed approach establishes a direct a priori relationship between specific topographic patterns on MRI and "gold standard" of pathology which can then be used to predict underlying dementia pathology in new incoming patients...
  10. pmc Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease
    Clifford R Jack
    Department of Radiology, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Brain 133:3336-48. 2010
    ....
  11. pmc Brain β-amyloid load approaches a plateau
    Clifford R Jack
    From the Departments of Radiology, Mayo Clinic, Rochester, MN, USA
    Neurology 80:890-6. 2013
    ..To model the temporal trajectory of β-amyloid accumulation using serial amyloid PET imaging...
  12. pmc Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics
    Jennifer L Whitwell
    Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA
    Brain 135:794-806. 2012
    ..Our analysis suggested that imaging has the potential to be useful to help differentiate C9ORF72 from these other groups at the single-subject level...
  13. pmc MRI and MRS predictors of mild cognitive impairment in a population-based sample
    Kejal Kantarci
    Department of Radiology, Mayo Clinic, Rochester, MN, USA
    Neurology 81:126-33. 2013
    ..To investigate MRI and proton magnetic resonance spectroscopy (MRS) predictors of mild cognitive impairment (MCI) in cognitively normal older adults...
  14. pmc Alzheimer's disease diagnosis in individual subjects using structural MR images: validation studies
    Prashanthi Vemuri
    Department of Radiology, Mayo Clinic 200 1st St SW, Rochester, MN 55905, USA
    Neuroimage 39:1186-97. 2008
    ..To develop and validate a tool for Alzheimer's disease (AD) diagnosis in individual subjects using support vector machine (SVM)-based classification of structural MR (sMR) images...
  15. pmc Distinct anatomical subtypes of the behavioural variant of frontotemporal dementia: a cluster analysis study
    Jennifer L Whitwell
    Department of Radiology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Brain 132:2932-46. 2009
    ..Our findings suggest behavioural variant of frontotemporal dementia can therefore be subdivided into four different anatomical subtypes...
  16. pmc Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease
    Clifford R Jack
    Clifford R Jack, Mayo Clinic, Diagnostic Radiology, 200 First Street SW, Rochester, MN 55905, USA
    Brain 132:1355-65. 2009
    ..This model implies a complimentary role for MRI and PIB imaging in Alzheimer's disease, with each reflecting one of the major pathologies, amyloid dysmetabolism and neurodegeneration...
  17. doi request reprint Imaging measures predict progression in progressive supranuclear palsy
    Jennifer L Whitwell
    Department of Radiology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Mov Disord 27:1801-4. 2012
    ..The aim of this work was to determine whether the progressive supranuclear palsy rating scale, a measure of disease severity, is associated with neuroanatomical changes in progressive supranuclear palsy...
  18. pmc Update on the magnetic resonance imaging core of the Alzheimer's disease neuroimaging initiative
    Clifford R Jack
    Department of Radiology, Mayo Clinic, Rochester, MN, USA
    Alzheimers Dement 6:212-20. 2010
    ..These experimental sub-studies are designed to demonstrate the feasibility of acquiring useful data in a multicenter (but single vendor) setting for these three emerging MRI applications...
  19. doi request reprint Modeling trajectories of regional volume loss in progressive supranuclear palsy
    Keith A Josephs
    Department of Neurology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Mov Disord 28:1117-24. 2013
    ..Decline is mainly linear but can be nonlinear for some regions. The frontal lobe and midbrain seem to be playing the most significant roles in the progressive worsening of clinical signs in progressive supranuclear palsy...
  20. pmc Thrombogenic microvesicles and white matter hyperintensities in postmenopausal women
    Limor Raz
    Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN, USA
    Neurology 80:911-8. 2013
    ..To determine the association of conventional cardiovascular risk factors, markers of platelet activation, and thrombogenic blood-borne microvesicles with white matter hyperintensity (WMH) load and progression in recently menopausal women...
  21. pmc Rates of brain atrophy and clinical decline over 6 and 12-month intervals in PSP: determining sample size for treatment trials
    Jennifer L Whitwell
    Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA
    Parkinsonism Relat Disord 18:252-6. 2012
    ..Sample size estimates suggest that treatment trials could be performed over this interval, with rate of midbrain atrophy providing the best outcome measure...
  22. pmc Comparison of different methodological implementations of voxel-based morphometry in neurodegenerative disease
    Matthew L Senjem
    Department of Radiology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Neuroimage 26:600-8. 2005
    ....
  23. pmc The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods
    Clifford R Jack
    Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    J Magn Reson Imaging 27:685-91. 2008
    ..The approach taken in ADNI to standardization across sites and platforms of the MRI protocol, postacquisition corrections, and phantom-based monitoring of all scanners could be used as a model for other multisite trials...
  24. ncbi request reprint Rates of cerebral atrophy in autopsy-confirmed progressive supranuclear palsy
    Keith A Josephs
    Department of Neurology, Mayo Clinic, 200 First Street NW, Rochester, MN 55905, USA
    Ann Neurol 59:200-3. 2006
    ..To determine the rates of cerebral atrophy and ventricular expansion in six patients with autopsy confirmed progressive supranuclear palsy (PSP) and multiple antemortem volumetric head MRI scans...